Doxercalciferol

Doxercalciferol
Names
	IUPAC name (1S,3R,5Z,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraene-1,3-diol
	Other names 1-Hydroxyergocalciferol; 1-Hydroxyvitamin D2; 1α-Hydroxyergocalciferol; 1α-Hydroxyvitamin D2; Hectorol; TSA 840
Identifiers
CAS Number	54573-75-0 ;
3D model (JSmol)	Interactive image;
ChEBI	CHEBI:4712;
ChEMBL	ChEMBL1200810 ;
ChemSpider	4444554 ;
DrugBank	DB06410 ;
ECHA InfoCard	100.170.997
IUPHAR/BPS	2790;
PubChem CID	5281107;
UNII	3DIZ9LF5Y9 ;
CompTox Dashboard (EPA)	DTXSID1034214 ;
	InChI InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1 Key: HKXBNHCUPKIYDM-CGMHZMFXSA-N ; InChI=1/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1 Key: HKXBNHCUPKIYDM-CGMHZMFXBN;
	SMILES O[C@@H]1CC(\C(=C)[C@@H](O)C1)=C\C=C2/CCC[C@]3([C@H]2CC[C@@H]3[C@@H](/C=C/[C@H](C)C(C)C)C)C;
Properties
Chemical formula	C28H44O2
Molar mass	412.658 g·mol−1
Pharmacology
ATC code	H05BX03 (WHO)
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

Doxercalciferol (or 1-hydroxyergocalciferol, trade name Hectorol) is drug for secondary hyperparathyroidism and metabolic bone disease.^[1] It is a synthetic analog of ergocalciferol (vitamin D₂). It suppresses parathyroid synthesis and secretion.^[2]

Doxercalciferol is the vitamin D₂ analogue of alfacalcidol.^[3] It undergoes 25-hydroxylation in the liver to become the active ercalcitriol, without the involvement of kidneys.^[4]

References

^ Sprague S M; Ho L T (2002). "Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient". Clinical Nephrology. 58 (2): 155–160. doi:10.5414/cnp58155. PMID 12227689.
^ "Doxercalciferol". Drugs.com.
^ Upton, R. A.; Knutson, J. C.; Bishop, C. W.; LeVan, L. W. (1 April 2003). "Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone". Nephrology Dialysis Transplantation. 18 (4): 750–758. doi:10.1093/ndt/gfg030. PMID 12637645.
^ "HECTOROL INJECTION (doxercalciferol)" (PDF). FDA accessdata. Retrieved 21 April 2018.

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.

[1] Sprague S M; Ho L T (2002). "Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient". Clinical Nephrology. 58 (2): 155–160. doi:10.5414/cnp58155. PMID 12227689.

[2] "Doxercalciferol". Drugs.com.

[3] Upton, R. A.; Knutson, J. C.; Bishop, C. W.; LeVan, L. W. (1 April 2003). "Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone". Nephrology Dialysis Transplantation. 18 (4): 750–758. doi:10.1093/ndt/gfg030. PMID 12637645.

[4] "HECTOROL INJECTION (doxercalciferol)" (PDF). FDA accessdata. Retrieved 21 April 2018.

[1]

[2]

[3]

[4]